李学松，男，主任医师，教授，博士生导师，博士后导师，现任北京大学第一医院泌尿外科副主任。兼任国家中医药管理局名词术语成果转化与规范推广项目编审专家、中华医学会泌尿外科分会泌尿男科工程学组委员(CUA)、中国机器人医师分会泌尿外科学组委员、中国医师协会泌尿外科医师分会(CUDA)委员兼副总干事、中国医师协会毕业后医学教育外科专业委员会副主任委员、北京医学会泌尿外科学分会青年委员会副主任委员、北京医学会泌尿外科分会尿路修复及重建学组副组长、北京癌症防治学会泌尿系肿瘤工作委员会主任委员、中国医促会泌尿生殖委员会委员、中国研究型医院泌尿外科青年委员会副主任委员、北京健康促进会泌尿外科专业委员会委员。
姓名
性别
专业
临床职称
教学职称
毕业院校
执业地点
科室
泌尿系肿瘤和输尿管疾病的开放及微创治疗。复杂疑难的肾脏、输尿管及膀胱修复重建。泌尿系肿瘤的腹腔镜和达芬奇机器人手术。
2004年9月-2009年8月，北京大学第一医院，主治医师；
2009年8月-2015年9月，北京大学第一医院，副主任医师；
2012年9月-2018年8月，北京大学第一医院，副教授；
2015年9月-至今，北京大学第一医院，主任医师；
2018年9月-至今，北京大学第一医院，科室副主任、教授。
泌尿系肿瘤的临床和基础研究。
在中英文杂志发表了二百余篇论文，第一或通讯作者发表SCI论文70余篇。参编或编译泌尿外科专业书籍15部，主译3部，主编3部。
2015年，获得第一届郭应禄泌尿外科青年医师奖；
2017年，获得华夏医学科技奖二等奖、中华医学科技奖三等奖；
2018年，获得教育部高等学校科学研究优秀成果奖(教育部奖)二等奖，北京市科技进步三等奖；
2019年，获得世界华人泌尿外科学会新星奖，获得国之名医优秀风范奖；
2020年，获得北京医学会首都青年医学创新与转化大赛一等奖。
国家中医药管理局名词术语成果转化与规范推广项目编审专家
中华医学会泌尿外科分会泌尿男科工程学组委员(CUA)
中国机器人医师分会泌尿外科学组委员
中国医师协会泌尿外科医师分会(CUDA)委员兼副总干事
中国医师协会毕业后医学教育外科专业委员会副主任委员
北京医学会泌尿外科学分会青年委员会副主任委员
北京医学会泌尿外科分会尿路修复及重建学组副组长
北京癌症防治学会泌尿系肿瘤工作委员会主任委员
中国医促会泌尿生殖委员会委员
中国研究型医院泌尿外科青年委员会副主任委员
北京健康促进会泌尿外科专业委员会委员
1.HeA,HeS,HuangC,...LiX*etal.MTDHpromotesmetastasisofclearcellrenalcellcarcinomabyactivatingSND1-mediatedERKsignalingandepithelial-mesenchymaltransition.Aging(AlbanyNY).2020;12(2):1465-1487.(IF4.831)
2.ZhanY,ChenZ,HeS,...LiX*etal.Longnon-codingRNASOX2OTpromotesthestemnessphenotypeofbladdercancercellsbymodulatingSOX2.MolCancer.2020;19(1):25.(IF15.302)
3.XiongS,ZhuW,LiX,ZhangP,WangH,LiX*.Intestinalinterpositionforcomplexureteralreconstruction:Acomprehensivereview.IntJUrol.2020;27(5):377-386.(IF2.445)
4.LuH,LiangY,GuanB,...LiX*etal.Aristolochicacidmutationalsignaturedefinesthelow-risksubtypeinuppertracturothelialcarcinoma.Theranostics.2020;10(10):4323-4333.(IF8.579)
5.WangJ,XiongS,FanS,...LiX*etal.AppendicealOnlayFlapUreteroplastyfortheTreatmentofComplexUreteralStrictures:InitialExperienceofNinePatients.JEndourol.2020;34(8):874-881.(IF2.322)
6.JiG,HuangC,HeS,...LiX*etal.Comprehensiveanalysisofm6Aregulatorsprognosticvalueinprostatecancer.Aging(AlbanyNY).2020;12(14):14863-14884.(IF4.831)
7.XiongS,WangJ,ZhuW,...LiX*etal.OnlayRepairTechniquefortheManagementofUreteralStrictures:AComprehensiveReview.BiomedResInt.2020;2020:6178286.(IF2.276)
8.FanS,YinL,YangK,...LiX*etal.Posteriorlyaugmentedanastomoticureteroplastywithlingualmucosalonlaygraftsforlongproximalureteralstrictures:Tencasesofexperience.JEndourol.2020.(IF2.322)
9.ChengS,FanS,WangJ,...LiX*etal.Laparoscopicandroboticureteroplastyusingonlayflaporgraftforthemanagementoflongproximalormiddleureteralstrictures:ourexperienceandstrategy[J].InternationalUrologyandNephrology,2020(7):1-10.(IF1.843)
10.BaoGuan#,ShiyingTang#,YonghaoZhan#,YifanLi,DongFang,DingPeng,YanqingGong,ShimingHe,LeiZhang,KunlinYang,GengyanXiong,LiboLiu,QunHe,XuesongLi*,LiqunZhou*.Prognosticperformanceofthe1973and2004WHOgradingclassificationinuppertracturothelialcarcinoma.UrolOncol.2019.(IF3.397)
11.YifanLi#,BaoGuan#,JingtaoLiu#,ZhongyuanZhang,ShimingHe,YonghaoZhan,BoxingSu,HaiboHan,XiaochunZhang,BoqingWang,XuesongLi*,LiqunZhou*,WeiZhao*.MicroRNA-200bisdownregulatedandsuppressesmetastasisbytargetingLAMA4inrenalcellcarcinoma.EBioMedicine.2019.(IF6.183)
12.YifanLi#,ShimingHe#,AnbangHe,BaoGuan,GuangzheGe,YonghaoZhan,YucaiWu,YanqingGong,DingPeng,ZhengqingBao,XuesongLi*,LiqunZhou*.Identificationofplasmasecretedphosphoprotein1asanovelbiomarkerforuppertracturothelialcarcinomas.BiomedPharmacother.2019;113:108744.(IF3.457)
13.WenlongZhong#,PengHong#,GuangpuDing#,KunlinYang,XuesongLi*,JunshengBao,GuochangBao,LiangCui,ChangpingMen,ZheLi,PengZhang,NingChuandLiqunZhou*.Technicalconsiderationsandoutcomesforilealureterreplacement:aretrospectivestudyinChina.BMCSurgery,2019;19:9.(IF1.692)
14.PengHong#,ZiaoLi#,DongdongZhu#,LiyanZhuang,KunlinYang,HanHao,XuesongLi*,LiqunZhou*.ASimpleModificationfortheUsageofFlexibleCystoscopeinModifiedLaparoscopicPyeloplastyforUreteropelvicJunctionObstructionwithRenalCalculi:AFlexibleGuidingTube.UrolInt.2019;102(3):262-268.(IF1.508)
15.YifanLi#,DongFang#,ZhengqingBao#,AnbangHe,BaoGuan,ShimingHe,YonghaoZhan,YanqingGong,XuesongLi*,LiqunZhou*.Highaspartatetransaminase/alaninetransaminaseratiopredictspoorprognosisinpatientswithlocalizeduppertracturothelialcancer:apropensityscore-matchedstudyinalargeChinesecenter.OncoTargetsTher,2019;12:2635-2648.(IF2.656)
16.PengHong,YukunCai,ZiaoLi,ShuboFan,KunlinYang,HanHao,QunHe,XuesongLi*,LiqunZhou*.ModifiedLaparoscopicPartialUreterectomyforAdultUreteralFibroepithelialPolyp:TechniqueandInitialExperience.UrolInt.2018;102(1):13-19.(IF1.508)
17.ZhuoJia#,YanqingGong#,CuijianZhang,ZhengqingBao,XuesongLi*,HanHao,GengyanXiong,LeiZhang,DongFang,ZhisongHe,LiqunZhou*.Segmentalureterectomycanbeperformedsafelyinpatientswithurothelialcarcinomaofdistalureter.CanUrolAssocJ.2018;13(7).(IF1.179)
18.YifanLi#,YanqingGong#,XianghuiNing,DingPeng,LiboLiu,ShimingHe,KanGong,CuijianZhang*,XuesongLi*andLiqunZhou*.DownregulationofCLDN7duetopromoterhypermethylationisassociatedwithhumanclearcellrenalcellcarcinomaprogressionandpoorprognosis.JExpClinCancerRes.2018;37(1):276.(IF6.217)
19.YonghaoZhan,ZhicongChen,YifanLi,AnbangHe,ShimingHe,YanqingGong,XuesongLi*andLiqunZhou*.Longnon-codingRNADANCRpromotesmalignantphenotypesofbladdercancercellsbymodulatingthemiR-149/MSI2axisasaceRNA.JExpClinCancerRes.2018;37(1):273.(IF6.217)
20.AnbangHe#,ShimingHe#,XuesongLi*,LiqunZhou*.ZFAS1:AnovelvitaloncogeniclncRNAinmultiplehumancancers.CellProliferation.2018;66(4):e12513.(IF4.936)
21.DingPeng,GuangzheGe,ZhengzhengXu,QinMa,YueShi,YuanyuanZhou,YanqingGong,GengyanXiong,CuijianZhang,ShimingHe,ZhisongHe,XuesongLi*,WeiminCi*andLiqunZhou*.DiagnosticandprognosticbiomarkersofcommonurologicalcancersbasedonaberrantDNAmethylation.Epigenomics.2018;10(9):1189-1199.(IF4.979)
22.ZhicongChen#,YonghaoZhan#,JieshanChi#,ShuyuanGuo#,XinliangZhong,AnbangHe,JianrongZheng,YanqingGong,XuesongLi*,LiqunZhou*.UsingmicroRNAsasNovelPredictorsofUrologicCancerSurvival:AnIntegratedAnalysis.EBioMedicine.2018;34:94-107.(IF6.183)
23.GuangzheGe#,DingPeng#,ZiyingXu#,BaoGuan,ZijuanXin,QunHe,YuanyuanZhou,XuesongLi*,LiqunZhou*andWeiminCi*.Restorationof5-hydroxymethylcytosinebyascorbateblockskidneytumourgrowth.EMBOReports.2018;19(8):e45401.(IF8.749)
24.DingPeng,GuangzheGe,YanqingGong,YonghaoZhan,ShimingHe,BaoGuan,YifanLi,ZiyingXu,HanHao,ZhisongHeGengyanXiong,CuijianZhang,YueShi,YuanyuanZhou,WeiminCi*,XuesongLi*andLiqunZhou*.VitaminCincreases5-hydroxymethylcytosinelevelandinhibitsthegrowthofbladdercancer.ClinEpigenetics.2018;10(1):94.(IF6.091)
25.BaoGuan#,YunchaoXing#,GengyanXiong#,ZhenpengCao,DongFang,YifanLi,YonghaoZhan,DingPeng,LiboLiu,XuesongLi*andLiqunZhou*.Predictivevalueofgenemethylationforsecondrecurrencefollowingsurgicaltreatmentoffirstbladderrecurrenceofaprimaryupper-tracturothelialcarcinoma.OncologyLetters.2018;15(6):9397-9405.(IF1.664)
26.DingPeng#,CuijianZhang#,YanqingGong*,HanHao,BaoGuan,XuesongLi*andLiqunZhou*.PrognosticsignificanceofHALP(hemoglobin,albumin,lymphocyteandplatelet)inpatientswithbladdercancerafterradicalcystectomy.ScientificReports.2018;8:794.(IF4.122)
27.DingPeng#,Cui-jianZhang#,QiTang,LeiZhang,Kai-weiYang,Xiao-tengYu,YanqingGong,Xue-songLi*,Zhi-songHeandLi-qunZhou*.Prognosticsignificanceofthecombinationofpreoperativehemoglobinandalbuminlevelsandlymphocyteandplateletcounts(HALP)inpatientswithrenalcellcarcinomaafternephrectomy.BMCUrol,2018,18:20.(IF1.792)
28.DongFang#,ShimingHe#,GengyanXiong#,NirmishSingla,ZhenpengCao,LeiZhang,XuesongLi*andLiqunZhou*.Comparisonofclinicopathologiccharacteristics,epigeneticbiomarkersandprognosisbetweenrenalpelvicandureteraltumorsinuppertracturothelialcarcinoma.BMCUrol.2018;18(1):22.(IF1.792)
29.BaoGuan#,YicongDu#,XiaohongSu#,ZhenpengCao,YifanLi,YonghaoZhan,DingPeng,GengyanXiong,DongFang,YiDing,ShimingHe,YanqingGong,QunHe,XuesongLi*andLiqunZhou*.Positiveurinaryfluorescenceinsituhybridizationindicatespoorprognosisinpatientswithuppertracturothelialcarcinoma.Oncotarget.2018;9(18):14652-14660.
30.Run-QiGuo#,Geng-YanXiong#,Kai-WeiYang,LeiZhang,Shi-MingHe,Yan-QingGong,,QunHe,Xue-YingLi,Zi-ChengWang,Zhen-QingBao,Xue-SongLi*,KaiZhang,Li-QunZhou*.Detectionofurothelialcarcinoma,uppertracturothelialcarcinoma,bladdercarcinoma,andurothelialcarcinomawithgrosshematuriausingselectedurine-DNAmethylationbiomarkers:Aprospective,single-centerstudy.UrolOncol.2018;36(7):342.e15-342.e23.(IF3.397)
31.ShiyingTang,HanHao,DongFang,WeiZheng,PengGe,XiaohongSu,QunHe,XinyuYang,QiShen,XuesongLi*,WeiYu,JianLin,LiqunZhou.Prostatecancerincidentallydiscoveredatthetimeofradicalcystoprostatectomydoesnotdecreaseoverallsurvival:ResultsfromalargeChinesemedicalcenter.IntBrazJUrol.2018;44(2):258-266.(IF0.976)
32.PengHong,GuangpuDing,DongdongZhu,KunlinYang,JinhongPan*,XuesongLi*,ZhipengChen,LeiZhang,QiTang,HanHao,ZhansongZhouandLiqunZhou.Head-to-HeadComparisonofModifiedLaparoscopicPyeloplastyandRobot-AssistedPyeloplastyforUreteropelvicJunctionObstructioninChina.UrolInt.2018;101(3):337-344.(IF1.508)
33.GengyanXiong#,LinYao#,PengHong#,LiYang,WeiminCi,LiboLiu,QunHe,KanGong,XuesongLi*andLiqunZhou*.Aristolochicacidcontainingherbsinducegender-relatedoncologicaldifferencesinuppertracturothelialcarcinomapatients.CancerManagRes.2018;10:6627-6639.(IF3.702)
34.WenlongZhong#,LinYao#,HaoranCui,KunlinYang,GangWang,TaoXu,XiongjunYe,XuesongLi*,LiqunZhou*.Laparoscopicureteralreimplantationwithextracorporealtailoringanddirectnippleureteroneocystostomyforadultobstructivemegaureter:long-termoutcomesandcomparisontoopenprocedure.IntUrolNephrol.2017;49(11):1973-1978.(IF1.692)
35.ShiyingTang#,GuochenNiu#,DongFang,ZiguangYan,BihuiZhang,XuesongLi*,MinYang*,LiqunZhou*.Thediagnosisandendovasculartherapyofrenalarteryaneurysm:A32-patientcasereport.Medicine(Baltimore).2017;96(47):e8615.(IF2.028)
36.WenlongZhong#,YicongDu#,KunlinYang,StevenMeng,RongchengLin,XuesongLi*,LiyanZhuang,LinCai,HaoranCui,ZhisongHe,andLiqunZhou.IlealUreterReplacementCombinedwithBoariFlap-PsoasHitchtoTreatFull-LengthUreteralDefects:TechniqueandInitialExperience.Urology.2017;108:201-206.(IF2.3)
37.Zhen PengCao,BaoGuan,Guang ZhiZhao,DongFang,Geng YanXiong,XuesongLi*,Li QunZhou.ValidationofthePretreatmentNeutrophil to LymphocyteRatioasaPrognosticFactorinaLargeCohortofChinesePatientswithUpperTractUrothelialCarcinoma.ChinMedJ(Engl).2017,130(17):2063-2068.(IF1.596)
38.YonghaoZhan,YifanLi,BaoGuan,ZichengWang,DingPeng,ZhicongChen,AnbangHe,ShimingHe,YanqingGong,XuesongLi*andLiqunZhou*.Longnon-codingRNAHNF1A-AS1promotesproliferationandsuppressesapoptosisofbladdercancercellsthroughupregulatingBcl-2.Oncotarget.2017;8(44):76656-76665.(IF5.168)
39.YonghaoZhan#,YifanLi#,BaoGuan#,XiaoyingChen,ZhicongChen,AnbangHe,ShimingHe,YanqingGong,DingPeng,YuchenLiu,ZhimingCai,XuesongLi*andLiqunZhou*.Increasedexpressionoflongnon-codingRNACCEPRisassociatedwithpoorprognosisandpromotestumorigenesisinurothelialbladdercarcinoma.Oncotarget.2017;8(27):44326-44334.(IF5.168)
40.XiaohongSu#,HanHao#,XuesongLi*,ZhisongHe,KanGong,CuijianZhang,LinCai,QianZhang,LinYao,YiDing,YanqingGong,DongFang,ZhengZhangandLiqunZhou*.Fluorescenceinsituhybridizationstatusofvoidedurinepredictsinvasiveandhigh-gradeuppertracturothelialcarcinoma.Oncotarget.2017;8(16):26106-26111.(IF5.168)
41.WenlongZhong#,RongchengLin#,LeiZhang,ChengyueJin,XuesongLi*,QunHe,KanGong,ZhisongHe,LiqunZhou*.Clinicopathologiccharacteristics,therapyandoutcomesofpatientswithprimaryureteralsmallcellcarcinoma:acaseseriesandsystematicreviewoftheliterature.OncoTargetsTher.2017;10:4105-4111.(IF2.656)
42.WenlongZhong#,LeiZhang#,JiajianMa,ShanShao,RongchengLin,XuesongLi*,GengyanXiong,DongFang,LiqunZhou*.Impactofaristolochicacidexposureononcologicoutcomesofuppertracturothelialcarcinomaafterradicalnephroureterectomy.OncoTargetsTher.2017;10:5775-5782.(IF2.656)
43.WenlongZhong,YicongDu,LeiZhang,XuesongLi*,CuijianZhang,DongFang,GengyanXiong,ZhisongHe,andLiqunZhou*.TheApplicationofInternalSuspensionTechniqueinRetroperitonealLaparoscopicPartialNephrectomyforRenalVentralTumors.BioMedResInt.2017;2017(5i):1-7.(IF2.583)
44.YunchaoXing#,GengyanXiong#,DongFang,XinyuYang,XuesongLi*,LiqunZhou*.PrognosticValueofGeneMethylationandClinicalFactorsinNon-Muscle-InvasiveUpperTractUrothelialCarcinomaAfterRadicalNephroureterectomy.ClinGenitourinCancer.2016;14(4):e371-e378.(IF2.539)
45.PeiLiu,XiaohongSu,GengyanXiong,XuesongLi*,LiqunZhou.DiagnosticUreteroscopyforUpperTractUrothelialCarcinomaisIndependentlyAssociatedwithIntravesicalRecurrenceafterRadicalNephroureterectomy.IntBrazJUrol.2016;42(6):1129-1135.(IF0.976)
46.XiaohongSu#,DongFang#,LeiZhang,GengyanXiong,HanHao,GuangzhiZhao,KunlinYang,YunchaoXing,XuesongLi*,LiqunZhou*.Treatmentstrategiesforuppertracturothelialcarcinoma(UTUC)ofasolitarykidney:asingle-institutionalanalysisof61cases.IntUrolNephrol.2016;48(10):1601-1608.(IF1.692)
47.LeiZhang,DongFang,XuesongLi*,LinYao,GengyanXiong,ZhisongHe,andLiqunZhou*.TransperitonealSubcostalAccessforUrologicLaparoscopy:ExperienceofaLargeChineseCenter.BioMedResInt.2016;2016(1):1-5.(IF2.583)
48.XiaohongSu,DongFang,XuesongLi*,GengyanXiong,LeiZhang,HanHao,YanqingGong,ZhengZhang,andLiqunZhou*.TheInfluenceofTumorSizeonOncologicOutcomesforPatientswithUpperTractUrothelialCarcinomaafterRadicalNephroureterectomy.BioMedResInt.2016;2016:1-7.(IF2.583).
49.LeiZhang,LinYao,XuesongLi*,MichaelA.S.Jewett,ZhisongHe,LiqunZhou*.Naturalhistoryofrenalcellcarcinoma:Animmunohistochemicalanalysisofgrowthrateinpatientswithdelayedtreatment.JFormosMedAssoc.2015;115(6):463-469.(IF2.452)
50.QiTang#,GengyanXiong#,XuesongLi*,DongFang,ChenguangXi,LeiZhang,KaiweiYang,LinYao,CuijianZhang,WeiYu,QunHe,KanGong,ZhisongHe,LiqunZhou*.Theprognosticimpactofsquamousandglandulardifferentiationforuppertracturothelialcarcinomapatientsafterradicalnephroureterectomy.WorldJUrol.2015;34(6):871-877.(IF2.981)
51.PeiLiu#,DongFang#,GengyanXiong,KaiweiYang,LeiZhang,LinYao,CuijianZhang,XuesongLi*,ZhisongHe,LiqunZhou*.ANovelandSimpleModificationforManagementofDistalUreterDuringLaparoscopicNephroureterectomyWithoutPatientRepositioning:ABulldogClampTechniqueandDescriptionofModifiedPortPlacement.JEndourol.2015;30(2):195-200.(IF2.038)
52.DongFang#,PeiLiu#,XuesongLi*,GengyanXiong,LeiZhang,NirmishSingla,GuangzhiZhao,QunHe,ZhisongHeandLiqunZhou*.Characteristicsandtreatmentoutcomesofpan-urothelialcellcarcinoma:adescriptiveanalysisof45patients.ScientificReports.2015;5(1):18014.(IF4.122)
53.YanqingGong,WeiQiu,XianghuiNing,XinyuYang,LiboLiu,ZichengWang,JianLin,XuesongLi*,YingluGuo*.CCDC34isup-regulatedinbladdercancerandregulatesbladdercancercellproliferation,apoptosisandmigration.Oncotarget.2015;6(28):25856-25867.(IF5.168)
54.KunlinYang#,LinCai#,LinYao,ZhengZhang,CuijianZhang,XinWang,JianqiangTang*,XuesongLi*,ZhisongHeandLiqunZhou.Laparoscopictotalpelvicexenterationforpelvicmalignancies:thetechniqueandshort-timeoutcomeof11cases.WorldJSurgOncol.2015;13(1):301.(IF1.792)
55.ZhengZhang#,DongFang#,XiaopengChen,XuesongLi*,GengyanXiong,LeiZhang,QunHeandLiqunZhou*.Predictiveroleofpreoperativehydronephrosisonpoorpathologicaloutcomesandprognosisinuppertracturothelialcarcinomapatients:Experiencefromanationwidehigh-volumecenterinChina.OncolLett.2015;10(5):3113-3122.(IF1.664)
56.XiaotengYu#,GangGuo#,XuesongLi#,CuijianZhang,LihuaHuang,DongFang,YiSong,XuZhang,andLiqunZhou*.RetrospectiveAnalysisoftheEfficacyandSafetyofSorafenibinChinesePatientswithMetastaticRenalCellCarcinomaandPrognosticFactorsRelatedtoOverallSurvival.Medicine(Baltimore).2015;94(34):e1361.(IF2.028)
57.LeiZhang,XuesongLi*,LiqunZhou*.NaturalHistoryofSmallRenalMasses.ChinMedJ(Engl).2015;128(9):1232–1237.(IF1.596)
58.GengyanXiong#,JinLiu#,QiTang,YuFan,DongFang,KaiweiYang1,FengXie,MinZhang,LeiZhang,LiboLiu,CuijianZhang,LinYao,LiYang,WeiminCi,WeiZhao,YanqingGong,QunHe,KanGong,ZhisongHe,GangWang,XuesongLi*,YingluGuoandLiqunZhou#.Prognosticandpredictivevalueofepigeneticbiomarkersandclinicalfactorsinuppertracturothelialcarcinoma.Epigenomics.2015;7(5):733-744.(IF4.979)
59.DongFang#,LeiZhang#,XuesongLi*,WeiYu,NirmishSingla,GuangzhiZhao,GengyanXiong,YiSong,QunHe,ZhisongHe,andLiqunZhou*.PresenceofConcomitantNon-muscle-invasiveBladderCancerinChinesePatientswithUpperTractUrothelialCarcinoma:RiskFactors,Characteristics,andPredictiveValue.AnnSurgOncol.2015;22(8):2789-2798.(IF3.857)
60.BentaoShi#,BoxingSu#,DongFang,YuanTang,GengyanXiong,ZhongqiangGuo,QunHe,XinyuYang,WeiZhao,YingluGuo,XuesongLi*andLiqunZhou*.HighexpressionofKPNA2definespoorprognosisinpatientswithuppertracturothelialcarcinomatreatedwithradicalnephroureterectomy.BMCCancer.2015;15(1):380.(IF3.288)
61.DongFang#,GengyanXiong#,XuesongLi*,YongmingKang,LeiZhang,GuangzhiZhao,XiaopengChen,LinYao,XiaoyuZhang,WeiYu,KanGong,YiSong,QunHe,ZhisongHe,LiqunZhou*,YingluGuo.Incidence,characteristics,treatmentstrategies,andoncologicoutcomesofsynchronousbilateraluppertracturothelialcarcinomaintheChinesepopulation.UrologicOncology.2015;33(2):66.e1-.e11.(IF3.397)
62.LeiZhang#,GengyanXiong#,DongFang,XuesongLi*,JinLiu,WeiminCi,WeiZhao,NirmishSingla,ZhisongHeandLiqunZhou*.Contralateraluppertracturothelialcarcinomaafternephroureterectomy:thepredictiveroleofDNAmethylation.JExpClinCancerRes.2015;34(1):5.(IF6.217)
63.KunlinYang#,LinYao#,XuesongLi*,CuijianZhang,TianyuWang,LeiZhang,DongFang,ZhisongHe,andLiqunZhou*.Amodifiedsuturetechniquefortransperitoneallaparoscopicdismemberedpyeloplastyofpelviuretericjunctionobstruction.Urology.2015;85(1):263-267.(IF2.3)
64.LeiZhang,WenshiYin,LinYao,XuesongLi*,DongFang,DaRen,ZhongyuanZhang,YuFan,QunHe,WeiminCi,ZhisongHe,andLiqunZhou*.GrowthPatternofClearCellRenalCellCarcinomainPatientswithDelayedSurgicalIntervention:FastGrowthRateCorrelateswithHighGradeandMayResultinPoorPrognosis.BioMedResInt.2015;2015(4):598134-598138.(IF2.583)
65.QiTang,YiSong,XuesongLi*,MaxwellMeng,QianZhang,JinWang,ZhisongHe,andLiqunZhou*.PrognosticOutcomesandRiskFactorsforPatientswithRenalCellCarcinomaandVenousTumorThrombusafterRadicalNephrectomyandThrombectomy:ThePrognosticSignificanceofVenousTumorThrombusLevel.BioMedResInt.2015;2015:163423.(IF2.583)
66.XiaotengYu,BingWang,XuesongLi*,GangLin,CuijianZhang,YangYang,DongFang,YiSong,ZhisongHeandLiqunZhou*.TheSignificanceofMetastasectomyinPatientswithMetastaticRenalCellCarcinomaintheEraofTargetedTherapy.BioMedResInt.2015;2015:176373.(IF2.583)
67.ZhongqiangGuo,JinLiu,LianZhang,BoxingSu,YunchaoXing,QunHe,WeiminCi,XuesongLi*andLiqunZhou*.KCNJ1inhibitstumorproliferationandmetastasisandisaprognosticfactorinclearcellrenalcellcarcinoma.TumourBiol.2014;36(2):1251-1259.(IF3.65)
68.DongFang#,LeiZhang#,XuesongLi*,GengyanXiong,XiaopengChen,WenkeHan,ZhisongHe,LiqunZhou*.Riskfactorsandtreatmentoutcomesofnewcontralateralupperurinaryurothelialcarcinomaafternephroureterectomy:theexperiencesofalargeChinesecenter.JCancerResClinOncol.2014;140(3):477-485.(IF3.282)
69.DongFang,QifuZhang,XuesongLi*,ChengQian,GengyanXiong,LeiZhang,XiaopengChen,XiaoyuZhang,WeiYu,ZhisongHe,andLiqunZhou*.NomogrampredictingrenalinsufficiencyafternephroureterectomyforuppertracturothelialcarcinomaintheChinesepopulation:exclusionofineligiblecandidatesforadjuvantchemotherapy.BioMedResInt.2014;2014(3):529186-10.(IF2.583)
70.XuesongLi*,DongFang,MatthewR.Cooperberg*,JaredM.Whitson,TomF.Lue,LiqunZhou,KatsutoShinohara.Long-termfollow-upofInternationalProstateSymptomScore(IPSS)inmenfollowingprostatebrachytherapy.WorldJUrol.2013;32(4):1061-1066.(IF2.981)
71.GengyanXiong,XiaopengChen,XuesongLi*,DongFang,LuxiaZhang,LiYang,LeiZhang,LinYao,ZhisongHe,LiqunZhou*.PrevalenceandfactorsassociatedwithbaselinechronickidneydiseaseinChina:a10-yearstudyof785upperurinarytracturothelialcarcinomapatients.JFormosMedAssoc.2013;113(8):521-526.(IF2.452)
72.RuiHe#,WeiYu#,XuesongLi*,LinYao,ZhisongHe,andLiqunZhou*.Laparoscopicureteralreimplantationwithextracorporealtailoringanddirectnippleureteroneocystostomyforadultobstructedmegaureter:anoveltechnique.Urology.2013;82(5):1171-1174.(IF2.3)
73.Xue-SongLi#,LinYao,KanGong,WeiYu,QunHe,Li-QunZhou,Zhi-SongHe*.Growthpatternofrenalcellcarcinoma(RCC)inpatientswithdelayedsurgicalintervention.JCancerResClinOncol.2012;138:269–274.(IF3.282)
74.HongjianZhu,ChengShen,XuesongLi*,XurenXiao,XianglongChen,QingjiangZhang,HuaWang,ZhisongHe,LiqunZhou.Laparoscopicpyeloplasty:acomparisonbetweenthetransperitonealandretroperitonealapproachduringthelearningcurve.UrolInt.2012;90(2):130-135.(IF1.508)
75.CuijianZhang,XuesongLi*,HanHao,WeiYu,ZhisongHeandLiqunZhou*.Thecorrelationbetweensizeofrenalcellcarcinomaanditshistopathologicalcharacteristics:asinglecenterstudyof1867renalcellcarcinomacases.BJUInt.2012;110(11PtB):E481-E485.(IF4.688)
76.CuijianZhang,XuesongLi*,ZhisongHe,YunxiangXiao,ShuqingLi,andLiqunZhou.Squamouscellcarcinomaoftheenlargedprostaticutricleinanadult.Urology.2012;79(2):e23-e24.(IF2.3)
77.XiaopengChen,XuesongLi*,MauriceM.Garcia,KanGong,YiSong,ZhisongHe,andLiqunZhou*.PrognosticfactorsinChinesepatientswithpenileinvasivesquamouscellcarcinoma.JAndrol.2012;33(6):1276-1281.
78.RuiHe,XinyuYang,XuesongLi*,ZhisongHe,andLiqunZhou.Cysticschwannomaofaseminalvesicle.JAndrol.2012;33(5):798-800.
79.WeiZheng,XuesongLi*,GangSong,ZhengZhang,WeiYu,KanGong,YiSong,QianZhang,ZhisongHe,YingluGuo,LiqunZhou*.Comparisonoflaparoscopicandopencystectomyforbladdercancer:asinglecenterof110casesreport.TranslAndrolUrol.2012;1(1):4-8.
1.杨昆霖,李晓颖,李学松*，周利群.术后辅助放疗在上尿路尿路上皮癌治疗中的应用现状[J].中华泌尿外科杂志,2020,41(5):394-396.
2.李新飞，程嗣达，孙永明，杨昆霖，张雷，李志华，贯华，黄燕波，郝瀚，李学松*，周利群.机器人辅助腹腔镜回肠膀胱扩大术治疗结核性膀胱挛缩的初步经验[J].临床泌尿外科杂志,2020(8):610-614.
3.程嗣达,李新飞,熊盛炜,樊书菠,王杰,朱伟杰,李子奡,丁光璞,俞婷,李万强,孙永明,杨昆霖,张雷,郝瀚,李学松*,周利群.机器人辅助腹腔镜上尿路修复手术：单一术者108例经验总结[J].北京大学学报(医学版)2020,52(4):771-779.
4.黄炳伟,王杰,张鹏,李喆,毕泗成,王强,岳才博,杨昆霖,李学松*,周利群.吲哚菁绿在复杂上尿路修复手术中的应用[J].北京大学学报:医学版,2020(4):651-656.
5.熊盛炜，王杰，朱伟杰，程嗣达，张雷，李学松*，周利群.二次肾盂成形术在复发性肾盂输尿管连接部梗阻中的研究进展[J].北京大学学报(医学版)，2020年4期。
6.郑蒙蒙,彭意吉,朱伟杰,杨昆霖,丁光璞,关豹,张磊,张进生,李学松*,周利群.三维影像重建测量积水肾体积参数在评估肾功能中的应用[J].现代泌尿外科杂志，2020,25(2):116-120
7.郑蒙蒙，丁光璞，朱伟杰，杨昆霖，樊书菠，关豹，李新飞，蔡宇坤，张进生，李学松*，周利群.术前三维影像重建在治疗肾盂输尿管连接部梗阻中的应用[J].北京大学学报(医学版),2020,52(4):705-710.
8.李世强,智静涛,武利兵,张锋,吴宪伟,李学松*.内镜治疗前列腺增生与尿道狭窄后并发感染的临床特征与治疗效果研究[J].中国性科学,2019,28(2):27-29.
9.李学松#,洪鹏,丁光璞,等.经腹完全腹腔镜肾输尿管全长切除术的关键技术总结(附光盘)[J].现代泌尿外科杂志,2018,23(10):728-731.
10.鲍正清#,方冬#,纪永鹏,李学松*,周利群*.阴茎癌腹股沟淋巴结清扫腹腔镜手术的新进展[J].现代泌尿外科杂志,2018,23(4):309-312,316.
11.余霄腾,张崔建,彭鼎,林榕城,唐琦,杨恺惟,张争,何志嵩,李学松*,周利群*.系统免疫炎症指数对于肾透明细胞癌患者术后预后的意义[J].中华临床医师杂志(电子版),2018,12(9):483-487.
12.钟文龙,李学松*,周利群*.内部悬吊技术在腹侧肾肿瘤后腹腔镜下肾部分切除术中的应用[J].微创泌尿外科杂志,2017,6(5):
13.关豹,曹振朋,彭鼎,李一帆,詹永豪,何世明,巩艳青,方冬,张雷,熊耕砚,李学松*,周利群*.上尿路尿路上皮癌患者膀胱复发灶的危险因素分析[J].中华泌尿外科杂志,2017,38(12):896-900.
14.曹振朋,关豹,方冬,熊耕砚,何世明,李学松*,周利群.年轻上尿路尿路上皮癌患者的临床病理和预后特征[J].现代泌尿外科杂志,2017,22(9):661-665.
15.唐世英,郝瀚,方冬,郑卫,彭东,詹永豪,鲍正清,李学松*,周利群*.保留女性生殖器官膀胱切除术的临床预后分析(附87例报告)[J].临床泌尿外科杂志,2017,32(10):741-745,750.
17.洪鹏,李一帆,方冬,,郭润碛,钟文龙,郝瀚,郑卫,葛鹏,巩艳青,张争*,李学松*,林健,周利群.体质指数对于根治性膀胱全切患者的临床特征和治疗结局的影响[J].肿瘤学杂志,2017,23(7):567-573.
18.朱雨泽,张雷,方冬,李学松*,周利群*.双肾嗜酸细胞瘤1例报告并文献复习[J].现代泌尿外科杂志,2016,21(9):734-735.
19.刘瑾,熊耕砚,唐琦,方冬,李学松*,周利群*.上尿路尿路上皮癌中RASSF1A基因启动子区域的甲基化状态及其临床意义[J].北京大学学报(医学版),2016,48(4):571-578.
20.苏晓鸿,方冬,张雷,熊耕砚,郝瀚,赵广智,杨昆霖,李学松*,周利群*.孤立肾上尿路尿路上皮癌61例临床诊疗分析[J].临床泌尿外科杂志,2016,31(12):1078-1082,1087.
22.钟文龙#,郝瀚#,苏晓鸿,方冬,郑卫,葛鹏,李学松*,周利群*.根治性膀胱全切术后患者临床病理及预后的性别差异(附427例报告)[J].临床泌尿外科杂志,2016,31(11):974-978.
23.姬超岳#,钟文龙#,张雷,张雷,李学松*,方冬,郝瀚,熊耕砚,周利群*.上尿路上皮癌根治术后对侧上尿路复发危险因素分析[J].临床泌尿外科杂志,2016,31(11):965-968,973.
24.鲍正清#,方冬#,岳才博,岳才博,蔡林,王天昱,李学松*,周利群*.原发性阴茎阴囊Paget病22例临床分析[J].北京大学学报(医学版),2016,48(4):638-642.
25.张雷,邓文涛,李学松*,等.高度怀疑恶性前列腺肿物6针法穿刺临床分析[J].现代泌尿外科杂志,2016,21(10):786-789.
27.张华俊#,唐世英#,张中元,唐琦,李学松*,周利群*.肾部分切除术术前肾周脂肪粘连的评估[J].现代泌尿外科杂志,2016,21(9):727-729.
28.钟文龙,杨昆霖,李学松*,等.回肠代输尿管术治疗双侧长段输尿管损伤一例报告并文献复习[J].中华泌尿外科杂志,2016,37(8):599-602
29.李学松#,钟文龙,吴帅,等.回肠代输尿管术临床应用及手术技巧(附光盘)[J].现代泌尿外科杂志,2016,21(4):245-248.DOI:10.3969/j.issn.1009-8291.2016.04.001.
30.余霄腾,张崔建,李学松*,等.索拉非尼治疗晚期肾癌患者的疗效及不良反应[J].现代泌尿外科杂志,2016,21(6):437-440.
32.李学松*,刘沛.腹腔镜及开放根治性膀胱全切-回肠原位新膀胱术的比较及应用体会[J].中华腔镜泌尿外科杂志(电子版),2015,(2):81-85.
34.杨昆霖,李学松*,周利群*.IUPU经腹腹腔镜联合膀胱软镜肾盂取石及肾盂成型术[J].泌尿外科杂志(电子版),2015,(3):4-6.
35.28.刘沛,李学松*,周利群*.经腹完全腹腔镜肾输尿管全长切除术及改良膀胱袖状切除术：IUPU技术[J].泌尿外科杂志(电子版),2015,(3):10-12,6.
36.29.唐琦,李学松*,周利群*.联合腹膜后及经腹入路腹腔镜治疗肾癌伴下腔静脉瘤栓[J].泌尿外科杂志(电子版),2015,(3):1-3.
37.杨昆霖,李学松*,周利群*.IUPU经腹腹腔镜巨输尿管体外裁剪、乳头再植术[J].泌尿外科杂志(电子版),2015,(3):7-9.
38.李学松#,周利群*,唐琦,等.联合后腹腔及经腹入路腹腔镜技术在肾癌伴下腔静脉瘤栓患者中的应用[J].北京大学学报(医学版),2015,47(4):569-570.
39.吴鑫,刘沛,朱雨泽,郑卫,唐琦,姚林,张崔建,郝瀚,李学松*,周利群.腹腔镜与开放根治性膀胱全切-回肠原位新膀胱术的疗效对比[J].现代泌尿外科杂志,2015,(4):229-233.
40.李学松#,杨昆霖,周利群.IUPU经腹腹腔镜肾盂成型术治疗成人肾盂输尿管连接处梗阻(附视频)[J].现代泌尿外科杂志,2015,(6):369-372.
41.刘沛#,吴鑫#,朱雨泽,唐琦,方冬,李学松*,郝金瑞,周利群*.回肠代输尿管术治疗医源性长段输尿管损伤[J].北京大学学报(医学版),2015,47(4):643-647.
42.刘沛,李学松*.嗜铬细胞瘤应行腹腔镜手术治疗[J].现代泌尿外科杂志,2014,19(10):683-685.
43.张雷,李学松*.T1b期肾癌应选择肾根治术[J].现代泌尿外科杂志,2014,(12):821-822.DOI:10.3969/j.issn.1009-8291.2014-12-016.
44.周亮亮,陈玉成,李学松*.膀胱嗜铬细胞瘤的诊治体会[J].首都医药,2014,(10):29-29,30.
45.杨昆霖,李学松*,周利群*.经腹腹腔镜输尿管体外裁剪、乳头再植术治疗成人梗阻性巨输尿管症的方法[J].北京大学学报(医学版),2014,46(4):511-514.
46.杨恺惟,张崔建,李学松*,等.小肾癌的临床病理特征:单中心1276例经验总结[J].北京大学学报(医学版),2014,46(5):790-793.
47.康永明,方冬,李学松*,等.双侧上尿路尿路上皮癌30例临床诊疗分析[J].首都医科大学学报,2014,(3):290-294.
48.刘沛,唐琦,李学松*,等.女性原发性尿道癌8例临床分析[J].现代泌尿外科杂志,2014,19(10):662-665,669.
49.张雷,姚林,李学松*,等.经腹腹腔镜肾切除手术的肾蒂处理技术:单一术者191例经验总结[J].北京大学学报(医学版),2014,46(4):537-540.
50.李学松#.经腹腹腔镜肾癌根治术的肾蒂处理经验:手术技巧及出血性并发症的腔镜下处理(附视频)[J].现代泌尿外科杂志,2013,18(1):6-8,12.
51.姚林,李学松*.肾脏小肿物的自然病程及诊治进展[J].中华泌尿外科杂志,2013,34(11):875-878.
52.杨恺惟,李学松*,周利群.肾脏黏液小管状和梭形细胞癌一例并文献回顾[J].中华临床医师杂志(电子版),2013,(8):3652-3654.DOI:10.3877/cma.j.issn.1674-0785.2013.08.080.
53.方冬,李学松*.腹腔镜上尿路手术经腹腔途径更有优势[J].现代泌尿外科杂志,2013,18(2):183-185.DOI:10.3969/j.issn.1009-8291.2013.02.028.
54.郑卫,汤坚强,李学松*.盆腔胸膜外孤立性纤维性肿瘤一例报告[J].中华泌尿外科杂志,2013,34(1):77.DOI:10.3760/cma.j.issn.1000-6702.2013.01.026.
55.吴翔,李涛,李学松*.肾脏平滑肌瘤5例分析并文献回顾[J].现代泌尿外科杂志,2013,18(4):398-400.DOI:10.3969/j.issn.1009-8291.2013.04.033.
56.杨飞亚,姚林,李学松*,等.腹腔镜双侧腹股沟淋巴结清扫术一例并文献复习[J].中华临床医师杂志(电子版),2013,(6):2696-2698.
57.邵光军,蔡林,李学松*,等.脐尿管癌:单中心30年经验总结[J].北京大学学报(医学版),2013,45(5):774-778.
58.唐琦,杨恺惟,郝翰,李学松*,周利群*.腹腔镜治疗双肾被膜下积液致Page肾一例及文献回顾[J].中华临床医师杂志(电子版),2013,(3):1278-1280.
59.方冬#,杨恺惟#,李学松*，等.腹腔镜治疗大体积肾癌的临床经验及与开放手术的比较[J].现代泌尿外科杂志,2013,18(6):553-556.
60.方冬,李学松*,谌诚,等.经腹腔与腹膜后腹腔镜肾癌根治术疗效比较[J].现代泌尿外科杂志,2013,18(2):126-129..
61.杨恺惟#,方冬#,李学松*,等.腹腔镜下不同手术入路治疗大体积肾癌的效果比较[J].中华临床医师杂志(电子版),2013,(21):9458-9461.
62.王天昱,陈晓鹏,李学松*,等.前列腺癌近距离治疗的效果和不良反应分析[J].现代泌尿外科杂志,2013,18(4):322-328.
63.吴翔,李涛,高祥勋,李学松*.肾脏肿瘤穿刺活检病理分型与组织学分级诊断准确性分析[J].中华临床医师杂志(电子版),2012,06(15):4185-4189.
64.李子然,李学松*.关于包皮环切术的争议[J].中华临床医师杂志(电子版),2012,6(18):140-143.
65.张中元,李学松*,周利群*.肾脏肿瘤评分系统的研究新进展[J].微创泌尿外科杂志,2012,1(1):20-23.
66.申海涛,郝瀚,连庆文,李学松*,周利群.后腹腔镜下离断式肾盂成形术48例治疗体会[J].中华临床医师杂志(电子版),2012,06(15):4454-4455.
67.吴翔,李学松*,何志嵩*,周利群.舒尼替尼治疗转移性肾癌的进展[J].中华临床医师杂志(电子版),2012,6(3):655-658.
68.张中元,唐琦,李学松*,等.R.E.N.A.L.肾肿瘤评分系统用于保留肾单位手术的临床分析[J].北京大学学报(医学版),2012,44(4):539-543.
69.郑卫,吴鑫,张雷,宋刚,张争,龚侃,宋毅,李学松*,何志嵩*,周利群.腹腔镜膀胱全切手术:单中心60例学习曲线结果分析[J].北京大学学报(医学版),2012,44(4):558-562.
70.胡佩胜,何睿,杨新宇,李学松*,周刊群,何志嵩,郭应禄.腹腔镜治疗精囊囊性神经鞘瘤一例并文献回顾[J].中华临床医师杂志(电子版),2012,6(3):714-715.
71.毕金文,周亮亮,李学松*,等.后肾腺瘤的临床及病理分析并文献复习[J].中华临床医师杂志(电子版),2011,05(3):868-870.
72.王天昱,陈晓鹏,李学松*,等.前列腺特异性抗原和Gleason评分对前列腺癌患者核素骨扫描结果的预测价值[J].北京大学学报(医学版),2012,44(4):528-534.
73.陈晓鹏,汤坚强,李学松*,等.回肠代输尿管术治疗长段输尿管缺损一例报道并文献复习[J].中华临床医师杂志(电子版),2011,05(8):2410-2413.
74.刘荣耀,赵鹏举,李学松*,等.经腹腔完全腹腔镜肾输尿管全长切除术治疗上尿路尿路上皮癌[J].北京大学学报(医学版),2011,43(4):531-534.
75.谌诚,周亮亮,李学松*,等.嗜铬细胞瘤诊疗:单中心142例报告[J].中华泌尿外科杂志,2011,32(1):35-37.
76.吴翔,于楠,高莹,李学松*,等.舒尼替尼致转移性肾细胞癌患者甲状腺功能异常的临床分析[J].中华临床医师杂志(电子版),2011,05(3):659-662.DOI:10.3877/cma.j.issn.1674-0785.2011.03.005.
77.张崔建,杨新宇,李学松*,等.肾脏非成熟囊性畸胎瘤一例报道及文献回顾[J].中华临床医师杂志(电子版),2010,04(12):2563-2566.DOI:10.3877/cma.j.issn.1674-0785.2010.12.042.
78.荣建红,张岩,李学松*,等.泌尿系子宫内膜异位症的诊断及治疗(附22例报告)[J].北京大学学报(医学版),2010,42(4):461-464.DOI:10.3969/j.issn.1671-167X.2010.04.023.
79.李学松#,宋毅,龚侃,等.舒尼替尼治疗转移性肾脏透明细胞癌的临床研究[J].中华外科杂志,2010,48(5):375-377.DOI:10.3760/cma.j.issn.0529-5815.2010.05.015.
80.李学松#,龚侃,孙国锋,等.Bcl-2和Bax在前列腺癌不同周期时相的表达[J].中华外科杂志,2008,46(10):768-771.DOI:10.3321/j.issn:0529-5815.2008.10.013.
81.李日清,李学松*,张祥华,等.原发性附睾肿瘤——附42例报告[J].中华临床医师杂志(电子版),2007,1(7):14-17.DOI:10.3969/j.issn.1674-0785.2007.07.006.
82.李学松#,李淑清,何志嵩,等.射频消融治疗肾肿瘤[J].中华临床医师杂志(电子版),2007,1(7):7-10.DOI:10.3969/j.issn.1674-0785.2007.07.003.
83.李学松#,李日清,张祥华,等.腹腔镜在苗勒管持续存在综合征诊断治疗中的应用——病例报告附录像[J].中华临床医师杂志(电子版),2007,1(7):50-51.DOI:10.3969/j.issn.1674-0785.2007.07.017.
84.李学松#,周利群,何志嵩,等.聚集素在前列腺癌细胞不同周期时相的表达[J].中华泌尿外科杂志,2006,27(1):36-39.
85.李学松#,厉将斌,梁云燕,等.紫龙金联合雌二醇氮芥对小鼠前列腺癌体内抑瘤作用的研究[J].中华泌尿外科杂志,2005,26(12):803-805.
86.李学松#,肖云翔,周利群,等.成人前列腺囊高分化鳞癌一例[J].中华外科杂志,2005,43(2):135.
87.李学松#,白龙伟,陈捷,等.肾脏平滑肌瘤三例报告[J].中华泌尿外科杂志,2004,25(10):675.
88.李学松#,梁云燕,王代树,等.紫龙金对前列腺癌细胞系DU-145的体外作用[J].中华实验外科杂志,2004,21(6):720-722.
89.李学松#,梁云燕,王代树,等.复方中药紫龙金对前列腺癌的体外作用[J].中华泌尿外科杂志,2004,25(8):516-520.
90.李学松#,梁云燕,王代树,等.复方中药紫龙金对前列腺癌细胞系LNCaP的体外作用[J].中国中西医结合杂志,2004,24(7):621-624.
91.李学松#,何志嵩*.激素难治性前列腺癌治疗进展[J].中国肿瘤,2003,12(12):699-703.[1]